Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies and precision immune technologies. The news flow around MiNK centers on its progress in oncology, graft-versus-host disease (GvHD), transplantation, and severe pulmonary inflammatory disease, reflecting the company’s focus on immune reconstitution and immune modulation.
News updates commonly highlight clinical trial milestones for its lead iNKT therapy agenT-797, including Phase 1 and Phase 2 studies in checkpoint-refractory solid tumors, GvHD prevention in allogeneic stem cell transplantation, and critical pulmonary immune failure. MiNK also reports on preclinical and translational data for next-generation programs such as MiNK-215, an IL-15–enhanced, FAP-targeting CAR-iNKT therapy designed to remodel the tumor stroma and enhance anti-tumor immunity.
Investors following INKT news can expect coverage of peer-reviewed publications, late-breaking presentations at scientific meetings, grant awards from agencies such as NIH and the Department of Defense, and philanthropic funding supporting GvHD and transplant-related studies. Corporate news items also include quarterly financial results, at-the-market equity program updates, and leadership and board appointments that the company associates with advancing its iNKT platform toward pivotal development.
This news page aggregates MiNK Therapeutics’ press releases and related market-moving announcements in one place, making it easier to track clinical data readouts, regulatory and funding developments, and strategic initiatives involving its allogeneic iNKT cell therapy pipeline.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company, reported significant Q2 2025 milestones and financial results. The company achieved a notable breakthrough with a durable complete remission in metastatic testicular cancer using their agenT-797 therapy, published in Nature's Oncogene.
MiNK secured substantial funding through two non-dilutive grants from the Department of Defense for GvHD research and raised $13 million through equity sales post-Q2, extending their cash runway beyond mid-2026. The company reported a Q2 2025 net loss of $4.2 million ($1.06 per share) compared to $2.7 million in Q2 2024, with cash and equivalents of $1.6 million at quarter-end.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing innovative invariant natural killer T (iNKT) cell therapies, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, before market opening.
The company will host a conference call and webcast at 8:30 a.m. ET to discuss the quarterly results and provide a corporate update. Investors can access the call through dial-in numbers for New York (646-307-1963) and USA/Canada (800-715-9871) using Conference ID 1149380, or via webcast on the company's investor relations website.
MiNK Therapeutics (NASDAQ: INKT) announced a publication in Frontiers in Immunology highlighting their innovative iNKT cell therapy platform. The article focuses on their lead program agenT-797, an unmodified allogeneic iNKT therapy, which has shown promising results in solid tumors without requiring lymphodepletion or genetic modification.
The company reported a notable case where a patient with metastatic testicular cancer achieved complete remission using agenT-797 combined with anti-PD-1 therapy, remaining disease-free for over two years. Additionally, in a Phase 2 trial for second-line gastric cancer, the therapy demonstrated enhanced tumor infiltration and durable disease control.
MiNK is also advancing MiNK-215, an IL-15-armored, FAP-targeting CAR-iNKT cell therapy designed to overcome stromal barriers in resistant tumors.
MiNK Therapeutics (NASDAQ: INKT) announced a groundbreaking publication in Nature's Oncogene detailing a complete remission case in metastatic testicular cancer using their agenT-797 allogeneic iNKT cell therapy. The patient, who had previously failed multiple treatments including platinum-based chemotherapy and immunotherapies, achieved complete remission lasting over two years after a single infusion of agenT-797 with nivolumab.
The therapy demonstrated remarkable safety with no cytokine release syndrome or graft-versus-host disease. Additionally, MiNK presented promising Phase 2 trial data in gastric cancer showing extended survival beyond 12 months in several patients, with a separate case reporting 42% tumor reduction and nine months progression-free survival.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has scheduled its first quarter 2025 financial results release for May 15, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update.
Investors can access the conference call via dial-in numbers 646-307-1963 (New York) or 800-715-9871 (USA & Canada) using Conference ID 9822477. A live webcast and replay will be available through the company's investor relations website.
MiNK Therapeutics (NASDAQ: INKT) reported its Q4 and full year 2024 financial results, highlighting progress in developing allogeneic iNKT cell therapies. The company's lead candidate, AgenT-797, showed promising results in cancer treatment and inflammatory lung conditions, with an 80% survival rate in VV ECMO patients versus 10% in hospital controls.
Key developments include a Phase 2 trial in advanced gastric cancer, next-generation PRAME-TCR iNKTs development, and MiNK-215 showing anti-tumor activity in colorectal cancer models. The company secured a research collaboration with Autonomous Therapeutics and raised $5.8M in private financing.
Financial results show a year-end cash balance of $4.6M, reduced cash burn with operations using $9.6M in 2024 compared to $15.8M in 2023. Net loss improved to $10.8M ($2.86 per share) in 2024 from $22.5M ($6.54 per share) in 2023.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has scheduled its fourth quarter and full year 2024 financial results release for March 18th, 2025, before market opening.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring a corporate update and discussion of financial results. Investors can access the call via phone at 646-307-1963 (New York) or 800-715-9871 (USA & Canada) using Conference ID 8023784, or through the company's investor relations website.